Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case

  • Carla Meyer-Massetti
  • Simone Vaerini
  • Alexandra E. Rätz Bravo
  • Christoph R. Meier
  • B. Joseph Guglielmo
Research Article

DOI: 10.1007/s11096-011-9541-y

Cite this article as:
Meyer-Massetti, C., Vaerini, S., Rätz Bravo, A.E. et al. Int J Clin Pharm (2011) 33: 806. doi:10.1007/s11096-011-9541-y

Abstract

Background Starting in 2007, regulatory agencies strengthened label warnings for intravenous haloperidol. Based on adverse drug reaction (ADR) reports of QT prolongation and torsades de pointes, regulatory agencies recommended the use of continuous telemetry or advising against the intravenous administration in general. Intravenous haloperidol is commonly used as a first line treatment for acute delirium. Consequently, the extended warning has caused uncertainty among health care professionals. Objective The aim of this study is to critically evaluate the WHO global individual case safety report (ICSR) database VigiBase for QT prolongation, torsades and/or cardiac arrest involving intravenous haloperidol compared to other routes of administration and the antipsychotics olanzapine and quetiapine. Method All WHO safety reports (1972–2010) of cardiac reactions associated with haloperidol, quetiapine and olanzapine were evaluated, including dose, route of administration and patient risk factors. Reporting odds ratios for the 3 antipsychotics were calculated. Main outcome measure Number of submitted reports on different antipsychotics. Results The absolute number of ICSR regarding QT prolongation, torsades and/or cardiac arrest were: haloperidol (365 cases), olanzapine (489) and quetiapine (520). Reporting rates of haloperidol did not increase over the last two decades. 32% of the haloperidol cases involved oral, 16.4% intramuscular and 22.7% intravenous administration. The difference of the reporting odds ratios of haloperidol and quetiapine were not statistically significant. Olanzapine was associated with a slightly lower reporting odds ratio. Conclusion While regulatory agencies advise against the use of intravenous haloperidol, review of VigiBase does not reveal that the intravenous route is any more likely to be associated with cardiac adverse events. Furthermore, our results do not demonstrate any additional risk associated with haloperidol when compared with alternative agents. Although pharmacovigilance data does not routinely include a denominator regarding frequency of use, regulatory agencies are currently advising against the use of intravenous haloperidol based on pharmacovigilance, but the number of overall reports is greater for quetiapine and olanzapine when compared to haloperidol. Improved pharmacovigilance approaches are needed to more accurately address the safe, effective use of medicines.

Keywords

Adverse events Adverse drug reaction database Adverse drug reactions Antipsychotic agents Drug safety Drug related problems Medication safety Pharmacogviliance QT prolongation Torsades de pointes World Health Organization 

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Carla Meyer-Massetti
    • 1
  • Simone Vaerini
    • 1
  • Alexandra E. Rätz Bravo
    • 2
  • Christoph R. Meier
    • 1
    • 3
  • B. Joseph Guglielmo
    • 4
  1. 1.Clinical Pharmacy and Epidemiology, Department of Pharmaceutical SciencesUniversity of BaselBaselSwitzerland
  2. 2.Regional Pharmacovigilance Center and Clinical Pharmacology and ToxicologyUniversity Hospital BaselBaselSwitzerland
  3. 3.Hospital PharmacyUniversity Hospital BaselBaselSwitzerland
  4. 4.Department of Clinical Pharmacy, School of PharmacyUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations